Multilaboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 1, 2005, Pages 49-58

  Favaloro, Emmanuel J ^a   Bonar, Roslyn ^a   Sioufi, John ^a   Wheeler, Michael ^a   Low, Joyce ^a   Aboud, Margaret ^a   Duncan, Elizabeth ^a   Smith, Julian ^a   Exner, Tom ^a   Lloyd, John ^a   Marsden, Katherine ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Activated protein C resistance; Antithrombin; Laboratory assessment; Lupus anticoagulant; Protein C; Protein S; Quality control

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; CHROMOGENIC SUBSTRATE; KAOLIN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S;

ACCURACY; ANTIGENICITY; AUSTRALIA AND NEW ZEALAND; BLOOD CLOTTING TIME; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RUSSELL VIPER VENOM TIME; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBINS; AUSTRALASIA; BLOOD COAGULATION TESTS; FACTOR V; HEMATOLOGY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTEIN S; PROTHROMBIN TIME; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; TIME FACTORS;

EID: 13844319163     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-863805     Document Type: Review

References (25)

1. Bertina RM. Genetic approach to thrombophilia. Thromb Haemost 2001;86:92-103
2. Simioni P. The molecular genetics of familial venous thrombosis. Bailliere's Best Pract Res Clin Haematol 1999; 12:479-503
3. Thiagarajan P, Shapiro SS. Lupus anticoagulants and antiphospholipid antibodies. Hematol Oncol Clin North Am 1998;12:1167-1192
4. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998;12:1141-1166
5. Rao AK, Kaplan R, Sheth S. Inherited thrombophilic states. Semin Thromb Hemost 1998;24(suppl 1):3-12
6. Field SL, Brighton TA, McNeil HP, Chesterman CN. Recent insights into antiphospholipid antibody-mediated thrombosis. Bailliere's Best Pract Res Clin Haematol 1999; 12:407-422
7. Haematology RCPA. QAP contact and program details. Available at: http://www.rcpaqap.com.au/. Accessed April 2, 2004
8. Favaloro EJ, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing, diagnosis and management of von Willebrand's disease: current practice in Australasia. Am J Clin Pathol 1999;112:712-719
9. Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J, on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999;82:1276-1282
10. Favaloro EJ, Thom J, Baker R. On behalf of the Australasian Society for Thrombosis and Haemostasis Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disease: results from the second Australasian laboratory survey. Blood Coagul Fibrinolysis 2000;11:729-738
11. Favaloro EJ, Bonar R, Sioufi J, et al. On behalf of the RCPA QAP in Haematology Haemostasis Committee. Laboratory diagnosis of von Willebrand disorder: current practice in the Southern Hemisphere. Am J Clin Pathol 2003;119:882-893
12. Jennings I, Kitchen S, Cooper PC, Rimmer JE, Woods TA, Preston FE. Further evidence that activated protein C resistance affects protein C coagulant activity assays. Thromb Haemost 2000;83:171-172
13. Jennings I, Kitchen S, Cooper P, Makris M, Preston FE. Sensitivity of functional protein S assays to protein S deficiency, a comparative study of three commercial kits. J Thromb Haemost 2003;1:1112-1114
14. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation. J Thromb Haemost 2003;1:748-753
15. Favaloro EJ, Orsag I, Bukuya M, McDonald D. A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 2002;34:348-355
16. Favaloro EJ, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT- based assays. Br J Biomed Sci 1999;56:23-33
17. Rylatt DB, Hohnen-Behrens C, Pilgrim RL, Dickenson LE, Neal M, Exner T. Detecting APC-resistant factor V: a functional method without plasma dilution. Blood Coagul Fibrinolysis 1999;10:359-366
18. Quehenberger P, Handler S, Mannhalter C, Kyrle PA, Speiser W. The factor V (Leiden) test: evaluation of an assay based on dilute Russell viper venom time for the detection of the factor V Leiden mutation. Thromb Res 1999;96:125-133
19. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276
20. Graf LL, Welsh CH, Qamar Z, Marlar RA. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003;119: 52-60
21. Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: An analysis of results from three surveys of the UK NEQAS for Blood Coagulation. Thromb Haemost 1997; 77:934-937
22. Favaloro EJ, Silvestrini R. Assessing the utility of anti-cardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multi-laboratory testing. Am J Clin Pathol 2002;118:548-557
23. Favaloro EJ, Silvestrini R. Assessing the utility of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multi-laboratory testing. Am J Clin Pathol 2002;118:548-557
24. 2-glycoprotein I antibody testing. Semin Thromb Hemost 2005;31:73-84
25. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832